Bomb Report – Lifestyle
Author:
Deerfield Group
FinVolution Group Reports Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results
March 17, 2026
Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
March 7, 2026
←
Previous Page
1
2